MAPT and Alzheimer disease: Finally, the TRAILBLAZER-ALZ 2 study (NCT04437511) of donanemab, a phase 3 clinical trial, was performed in 1800 patients with early symptomatic AD who had Aβ and tau pathologies (Table 1).